Recently, the U.S. FDA approved esketamine, a fast-acting drug derived from the anesthetic, ketamine, that is intended to aid the treatment-resistant population of people with depression. There are about 16.2 million Americans who suffer from major depression, and as many as a quarter of them reported achieving little to no results from available treatments, including FDA
Nasal spray could help those who have no success with available depression treatments
